pertuzumab,trastuzumab,Docetaxel
roche,zymeworks
['pertuzumab', '$zyme']
#asco22 poster $zyme 1l adv her2+ bc zani + chemo 90,5% orr, 95,2% dcr for comparison trast + pertuzumab + chemo 80,2% orr, 94,8% dcr
(cleopatra trial) patients in the zani study were slightly sicker ( ecog) and had slightly lower her2 expression ( ihc3+).
Biotech Investor, Former Scientist, M.D., Tweets since October 2019